MedPath

The effects of cholecalciferol and soy isoflavones in irritable bowel syndrome

Not Applicable
Conditions
Irritable Bowel Syndrome.
Irritable colon
Registration Number
IRCT2013112915582N1
Lead Sponsor
ational Nutrition and Food Technology Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
100
Inclusion Criteria

age 18-75 yrs; patients with Irritable Bowel Syndrome (IBS) according to ROME III criteria; BMI 18-25; no intestinal organic diseases; no intestinal infection; no history of chronic gastrointestinal and colorectal diseases; no intestinal major surgery; no regular use of antibiotics, anti-constipation and anti-diarrhea, immune suppressors, metocloperamide, cisaperide, difenoxilate, opium and non-steroidal anti-inflammatory drugs; no pregnancy and lactation; not athlete or bed rest; no history of breast cancer in herself or her family; no severe psychosis
Exclusion criteria: use of soy isoflavones or vitamin D one year before the study; use of soy milk or soy nuts during study; diet changes during study; use of artificial sweetener 2 days before study; no desire to complete the study; adverse effect of supplement; pregnancy during study

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical Outcomes (pain, flatulence, diarrhea, constipation ). Timepoint: before and after the 6 weeks. Method of measurement: IBS validated Module according to ROME-III criteria.
Secondary Outcome Measures
NameTimeMethod
Gut permeability. Timepoint: before and after 6 weeks. Method of measurement: The fecal serin protease.;Antioxidant status. Timepoint: before and after 6 weeks. Method of measurement: Serum total antioxidant capacity.;Inflammation status. Timepoint: before and after 6 weeks. Method of measurement: Serum tumor necrosis factor-alpha.
© Copyright 2025. All Rights Reserved by MedPath